Engineering cancer cells for self-destruction is a promising immunotherapy to promote antitumor immunity. Creative Biolabs provides a complete range of engineering HepG2 cell services, promotes your scientific immunotherapy research progress, and is your reliable partner.

Introduction of HepG2 Cell Line

The HepG2 cell line is a hepatoblastoma cell line derived from the liver tissue of a 15-year-old white male with a well-differentiated hepatocellular carcinoma. This cell line was mistakenly labeled as hepatocellular carcinoma, leading to considerable confusion for 40 years. HepG2 cells are immortalized cells and nontumorigenic cells with high proliferation rates and an epithelial-like morphology that perform many differentiated hepatic functions. These cells are adherent epithelial cells growing as monolayers in small aggregates. They do not possess critical markers of liver cells, including the expression of albumin and alpha- and gamma-fibrinogen. The cells will respond to stimulation with human growth hormone. The HepG2 cell line can serve as an appropriate model for hepatoblastoma.

Engineering Liver Cancer Cell Service

One reason for the development of cancer, among others, is that cells that have accumulated defects have lost the ability to destroy themselves. A new approach had been reported to use patients' own tumor cells to train their immune systems to find and kill cancer, eliciting potent and long-lasting T-cell immunity against melanomas. Expanding this approach to other cancer types provides a promising self-destructive strategy for cancer therapy. From this, Creative Biolabs develops a platform to engineer cancer cells for cancer immunotherapy.

HepG2 cells are commonly used as a model system in vitro for human liver cancer cells. Liver cancer cells such as HepG2 cells can be conditioned or engineered to mediate self-destruction. We provide engineering HepG2 cell services using viral transduction such as retrovirus, lentivirus, adenovirus, adeno-associated virus, or non-viral delivery system. Several strategies have been developed to design and construct a functional HepG2 cell for self-destruction as follows. These strategies provide huge promise for the future of personalized cancer immunotherapy and vaccine design.

In addition to engineering cancer cells, we also provide extensive validation and verification for studying processes of interest. Our scientific approach includes a series of performance evaluation experiments such as a few self-destruction assays in vitro, cytokine & chemokine production assessment ex vivo, toxicity assessment, etc. Our solutions include further custom tune-up and optimization to meet your requirements.

Our expert team has extensive expertise in cancer immunotherapy and is experienced at working with a variety of cell lines. Our complete portfolio of solutions sets us apart and allows us to achieve maximum efficiencies and speed up your research. If you are interested in partnering with us, please feel free to contact us to discuss your project.

Reference

1. Huang, H.; et al. Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy. Nature communications. 2019, 10(1): 1-15.

For Research Use Only | Not For Clinical Use